Challenges and Opportunities with Contemporary GDMT in NYHA Class II/III HFrEF

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

CVRx | Barostim

CVRx® develops Barostim™ Baroreflex Activation Therapy (BAT), a novel therapy that activates the autonomic nervous system through baroreceptor stimulation to improve the symptoms of heart failure.

Learn more by visiting the following link cvrx.com

Baroreflex Activation Therapy

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Challenges and Opportunities with Contemporary GDMT in NYHA Class II/III HFrEF

By CVRx | Barostim FEATURING William Abraham

202 views

July 31, 2024

Dr. Abraham discusses the challenges and opportunities with contemporary GDMT, Barostim's mechanism of action, and the post-market BeAT-HF trial results.

Comments 0